| GCT Clinical Trials |
|---|
|
Phase II: Paclitaxel in Patients with Ovarian Stromal Cancer Phase II: Bevacizumab in Patients with Recurrent Stromal Tumours of the Ovary Phase I: NCI Trial Search |
|
We comply with the
HONcode standard for trustworthy health information: verify here. |
| Runners For Research | ||
|
We've raised over $23,000 so far |
||
|
|
||
|
|
Sponsor a runner! | |
| Shop @ Amazon |
|---|
|
Shop On-line GCTF NZ gets a donation, you get a great price! |
|
|
| GCTF Warriors |
| Visit this group |
|
| |
|
New!
GCTRF Awards Research Grant to Finnish Researcher
-- Posted 21 November, 2011 We are pleased to announce the awarding of a grant to Dr. Mikko Anttonen from Helsinki, Finland. He put forward a proposal to identify a marker for GCT that is more specific than Inhibin, partly due to the fact that in Finland they do not generally use CT scans for monitoring. What his group also bring to the table is a collection of over 200 GCT samples that represents a significant increase for future research. In assessing Dr. Anttonen's proposal, one of advisory panel members stated: "This application has some very significant strengths. The applicant is a young investigator working within a program that has developed a unique granulosa cell tumor research resource i.e. 232 cases of GCT with follow-up and serum/tissue banked on some of the cases. This dedicated, clinically oriented GCT research program has outstanding potential to impact on GCT management. The applicant and his team have published important and exciting work on VEGF signaling in GCT, recently, highlighting a treatment option for patients with GCT. The applicant has the appropriate research and clinical training background to become a leader in GCT translational research." Additional information can be found here: Their most recent publication on the effectiveness of Avastin (Bevacizumab) on GCT "Dr. Anttonen's publications". | |
|
| |
|
Employer Donations are a Tremendous Way to Help We have recently received two donations from corporations as a result of the efforts put forth by a couple of our members! Vocollect, thanks to Stacey, and Becton Dickinson (or BD), thanks to Betty, both made generous contributions to our research fund. So we ask all of you to please, ask your employer about their charitable giving program. A new year is coming soon and most companies start their donation schedule all over again. It costs nothing to ask!! We are actively considering 2 additional grant requests which is only possible as long as we have funds available. | |
|
| |
|
Everything You Wanted to Know About GCT! OK, maybe not everything or maybe more than you wanted to know! Our first-ever intern, Haley Roberts, has written a report based on her research experience in Auckland, NZ during June-July. She spent 5 weeks in the lab with Dr. Shelling and our research crew watching GCT wiggle around in petri dishes, looking at reams of data all the testing produces, and from that has compiled her "GCT for Dummies". Have a read, even make a copy for your doctor, and if you have any questions, ask Haley! (she can be found through our GCTF Warriors group) | |
|
| |
|
GCT Research Roseanne Rosario, one of our researchers in NZ, recently made a presentation at an international conference in Milan, Italy. It presents more information on the nature of the FOXL2 gene. Check it out (uses popup window) And read the latest update from Dr. Andrew Shelling and our New Zealand research team (uses popup window) | |
|
| |
|
GCT in the News Haley has followed up her "GCT for Dummies" with a recent round of multimedia reports about her experience, the foundation, and her determination to make a difference. Check them out if you haven't already. Pittsburgh CBS News the Almanac - a local Pittsburgh Newspaper Powel, meanwhile, ran his way into the news in Christchurch and was a pre-race topic in Guernsey Marathon Newsletter | |
|
| |
|
| |
|
Wanted: Researchers to Investigate GCT GCTRF is dedicated to finding an effective treatment and is interested in providing funds for researchers who would work with us towards that goal. If you are a researcher, with an interest in GCT research, we invite you to consider submitting a research grant application. You can find more information about our grant program by clicking here. Our funding window for next year closes on 31 March, 2012. | |
|
| |
|
|
|
| |
|
GCT Survivors Weekend Presentations We've posted the currently available materials from our weekend at the link below. Click here. | |
|
We Changed Our Name We are a New Zealand-based, international foundation working to support GCT patients and fund GCT research all around the world. So, in order to more accurately reflect this global reach and focus on research we have changed our name to: Granulosa Cell Tumour Research Foundation This will take some time to filter through all of the "official" channels, and modify all our web pages and documents, but we will start using the new name and acronym (GCTRF) effective immediately. In conjunction with this change we have added the internet domain gctrf.org which currently point back to our current website. | |
|
| |
|
Website Issues with Internet Explorer 8 or 9 We have been informed, and confirmed, that there are some issues with Internet Explorer 8 or 9 that affect the ability of our supporters to login, or make a donation. While we try to resolve the issue, please try an alternate browser (e.g. Firefox, Chrome, Opera) or try the workaround shown here. We apologise for the inconvenience and please let us know any time you have a problem with our site! | |
|
| |
|
Welcome to the Granulosa Cell Tumour Research Foundation
Granulosa cell tumours (GCT) are a rare form of ovarian cancer. Statistics show that they make up a relatively small percentage of all ovarian cancers and GCT has therefore received less attention from researchers than some other cancers. Because GCT is rare, many oncologists are not readily familiar with the disease, few claim to be specialists in its treatment, and some doctors, reportedly, still think that GCT is not considered to be a cancer. Founded in 2004 as Granulosa Cell tumour Foundation New Zealand, our mission is to:
Why we push for researchOne of the most common descriptions of GCT in the medical community is: "Granulosa cell tumor of the ovary is an uncommon tumor of low malignant potential (LMP)" and many articles add that GCT has a "low rate of recurrence". Often this is presented as a comforting factor, implying that you do not have to worry that much about recurrence or dying of the disease. It is also known, however, that "Low-grade ovarian cancers and LMP tumours generally resist conventional cytotoxic chemotherapy." Several articles have also stated that 50% - 80% of women with recurrent GCT will die from the disease, just as our Founder, Sladjana (Sofi) Crosley, did. That is why we need research on GCT and why we have established the "Sladjana M. Crosley Fund for GCT Research". This is not always a "benign" disease and can recur at any point over your lifetime, even up to 35 years after your diagnosis. We need Supporting MembersMedical discoveries don't happen without research, and research doesn't happen without a steady flow of funding. Because we know that GCT tends to be non-responsive to normal, cytotoxic chemotherapy we have commissioned research designed to find molecular pathways through which GCT might be better controlled, and possibly cured. We need you to support this battle and want to enlist you as a "GCTRF Supporting Member". For a minimum, annual donation of at least $25 NZD, or more if you can possibly afford it, we will register you as a "GCTRF Supporting Member". By clicking on the "Donate Today" link you make a statement to yourself and us that you recognise the importance of this research and are joining the fight! In return, we will provide you with every bit of insight and information we can muster to help you and your medical team. This includes complete updates from our research teams as we receive them; unrestricted access to our Case History database; the right to post messages on our forum; periodic newsletters from the foundation; and more services we are continuing to develop. GCTRF is a registered, 100% volunteer foundationThe foundation is registered with New Zealand Inland Revenue and the US Internal Revenue Service. When you donate to GCTRF you can depend on 100% of that donation going to researchers due to the fact that we are a totally volunteer organisation and have received a private grant to cover operating expenses. We pay no salaries and no director's fees. When you donate your hard-earned money you deserve to know that it is going to the purposes for which you donated! | |
| |
To register as a supporter of
GCTF New Zealand please provide the information below.
Rest assured that we do not share ANY information about our registered users with ANY
other organisation!
As a supporter of
GCTF New Zealand you can update the information below.
We do not share ANY information about our registered users with ANY
other organisation, we simply use it for internal purposes!
Being a "Cell Mate" means making yourself available as a contact/resource for someone else
in your area who is diagnosed with GCT. It is also a way to find out if
there are others in your area with GCT in case you want to share experiences or just
find some personal support in your fight with this rare disease.
The "Cell Mate" register will list the Country, State/Province, and City where we have
registered "mates". Clicking on the links will give someone the chance to
compose an e-mail enquiry that we will then forward to the registered "Cell Mates" in that
city. Then it will be up to the "mates" to respond back and take the situation
from there.
To register as a "Cell Mate" simply provide the basic information below.
Rest assured that we do not share ANY information about our registered users with ANY
other organisation!
And remember,
if anyone ever wants to contact you, WE will send you an email with their request and you will
have the option to reply.